Department of Hematology, Second affiliated Hospital of Kunming Medical University, Kunming 650101, PR China.
Oncol Rep. 2012 Jun;27(6):1815-22. doi: 10.3892/or.2012.1707. Epub 2012 Mar 7.
Multiple myeloma (MM) is a clonal B-cell malignancy charactered by the aberrant proliferation of malignant plasma cells in the bone marrow. MM is still an incurable malignancy. In this regard, novel treatments are urgently required. MUC1 (mucin 1), a type І transmembrane protein, is overexpressed and aberrantly glycosylated in many carcinomas particularly in MM resulting in an antigenically distinct molecule and may be a potential target for specific immunotherapy. In this study, we first designed a unique DNA vaccine, termed MUC1-2-VNTR (various number tandem repeats) to investigate whether the vaccine could specifically suppress tumor growth in a murine multiple myloma model. Our results showed that the constructed DNA vaccine pcDNA3.1-VNTR elicited both humoral and cellular tumor-specific immune responses in the MM mouse model leading to delay in tumor growth and prolonged survival of the mice. Consequently, our study indicates that this DNA vaccine shows promise to be used as a novel strategy for the treatment of MM.
多发性骨髓瘤（MM）是一种克隆 B 细胞恶性肿瘤，其特征是骨髓中恶性浆细胞的异常增殖。MM 仍然是一种无法治愈的恶性肿瘤。在这方面，迫切需要新的治疗方法。MUC1（粘蛋白 1）是一种 I 型跨膜蛋白，在许多癌特别是 MM 中过度表达和异常糖基化，导致抗原性不同的分子，可能是特异性免疫治疗的潜在靶点。在这项研究中，我们首先设计了一种独特的 DNA 疫苗，称为 MUC1-2-VNTR（不同数量串联重复），以研究该疫苗是否能特异性抑制鼠多发性骨髓瘤模型中的肿瘤生长。我们的结果表明，构建的 DNA 疫苗 pcDNA3.1-VNTR 在 MM 小鼠模型中引起了体液和细胞肿瘤特异性免疫反应，导致肿瘤生长延迟和小鼠存活时间延长。因此，我们的研究表明，这种 DNA 疫苗有望成为治疗 MM 的一种新策略。
